Benitec Biopharma regains Nasdaq compliance with $28.6M equity offering

Benitec Biopharma Inc.

Regained compliance with Nasdaq minimum stockholders' equity rule via $28.6M net proceeds from August 2023 offering.
As of June 30, 2023, stockholders' equity was below $2.5M requirement; offering resolved deficiency.
Offering included 875,949 common shares, 15,126,226 pre-funded warrants, and 16,002,175 common warrants at $1.93 per unit.
Nasdaq will continue to monitor compliance; non-compliance at next report could lead to delisting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.